A Comparison of Rocuronium 0.6 mg/kg and Remifentanil 2 µg/kg in Elderly Patients Over 80 Years

• Status: Completed
• Trial end date: 2020-12-13
• Target enrollment: 0
• Participant gender: All

Summary

The number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia.

During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of residual neuromuscular block when using NMBAs like rocuronium.

Remifentanil is a fentanyl analogue commonly used for induction since it also facilitates intubation. There is no risk of residual neuromuscular block, nonetheless circulatory side effects have been seen.

It is unknown which is superior concerning intubating conditions in elderly patients. Therefore, the aim of this study is to determine the effect on intubating conditions and laryngeal morbidity after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in patients with age ≥ 80 years. The hypothesis of this study is that rocuronium 0.6 mg/kg provides a higher proportion with excellent intubating conditions compared to remifentanil 2 µg/kg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Treatments: Remifentanil; Rocuronium

Criteria

Inclusion Criteria:

• Age ≥ 80

• Scheduled for elective operations (expected duration of anesthesia > 1 hour) under general anesthesia with intubation

• American Society of Anesthesiologists physical status classification (ASA) I to III

• Informed consent (see appendix 1)

• Read and understand Danish

Exclusion Criteria:

• Neuromuscular disease

• Known allergy to rocuronium, remifentanil or sugammadex

• Rapid sequence induction